← All trials
NCT05662410
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 26, 2022
- Primary completion
- Jun 26, 2023
- Completion date
- Dec 26, 2023
- First posted
- Dec 22, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kim's Eye Hospital, Seoul, South KoreaLead sponsor
- Kim's Eye Hospital, Seoul, South KoreaReponsible party - principal investigator
- Nune Eye Hospital, Seoul, KoreaCollaborator
- Kim's Eye Hospital, Seoul, South KoreaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.